How we treat patients with brain tumour during the COVID-19 pandemic

Weller, Michael ; Preusser, Matthias

Abstract: The COVID-19 pandemic has created major insecurities regarding whether we can and should maintain the current standards of diagnosis and treatment and access to care for patients with cancer. This is particularly true in the field of neuro-oncology, where the perceived benefit of therapeutic interventions is often low, although this notion is partially incorrect. We acknowledge that the recommendations for care of patients with cancer have become a moving target and that all recommendations are subject to modification based on national and institutional regulations. Still, some important considerations and proposals may apply broadly. First, it is important to note that old age and cardiovascular and pulmonary co-morbidities are the major risk factors for experiencing a severe course of and for dying of COVID-19, not chronic immunosuppression and cancer. Second, many of the considerations on how we should adapt clinical practice in neuro-oncology in view of COVID-19 that are now dominating discussions at local tumour boards, as well as on the institutional level and within societies of neuro-oncology, are not novel but have been valid before and only now have become a priority. More than ever, it seems to be mandatory to adhere to evidence-based medicine and not to prescribe potentially toxic, notably immunosuppressive systemic therapy where evidence for efficacy is low. Furthermore, it is more obvious now that oncologists must not miss the right time for advance care planning, that is, supporting patients in understanding and sharing their personal values, life goals and preferences regarding future medical care. The major psychological impact of transforming oncology care to teleconferences and videoconferences and of the important strict recommendation of social distancing must not be overlooked in a patient population that is characterised by significant prevalence of cognitive decline and by the general perception that their life span may not exceed the life span of the COVID-19 pandemic.

DOI: https://doi.org/10.1136/esmoopen-2020-000789

Posted at the Zurich Open Repository and Archive, University of Zurich
ZORA URL: https://doi.org/10.5167/uzh-191429
Journal Article
Published Version

The following work is licensed under a Creative Commons: Attribution-NonCommercial 4.0 International (CC BY-NC 4.0) License.

Originally published at:
Weller, Michael; Preusser, Matthias (2020). How we treat patients with brain tumour during the COVID-19 pandemic. ESMO Open, 4(Suppl 2):e000789.
DOI: https://doi.org/10.1136/esmoopen-2020-000789
How we treat patients with brain tumour during the COVID-19 pandemic

Michael Weller, Matthias Preusser

ABSTRACT
The COVID-19 pandemic has created major insecurities regarding whether we can and should maintain the current standards of diagnosis and treatment and access to care for patients with cancer. This is particularly true in the field of neuro-oncology, where the perceived benefit of therapeutic interventions is often low, although this notion is partially incorrect. We acknowledge that the recommendations for care of patients with cancer have become a moving target and that all recommendations are subject to modification based on national and institutional regulations. Still, some important considerations and proposals may apply broadly. First, it is important to note that old age and cardiovascular and pulmonary comorbidities are the major risk factors for experiencing a severe course of and for dying of COVID-19, not chronic immunosuppression and cancer. Second, many of the considerations on how we should adapt clinical practice in neuro-oncology in view of COVID-19 that are now dominating discussions at local tumour boards, as well as on the institutional level and within societies of neuro-oncology, are not novel but have been valid before and only now have become a priority. More than ever, it seems to be mandatory to adhere to evidence-based medicine and not to prescribe potentially toxic, notably immunosuppressive systemic therapy where evidence for efficacy is low. Furthermore, it is more obvious now that oncologists must not miss the right time for advance care planning, that is, supporting patients in understanding and sharing their personal values, life goals and preferences regarding future medical care. The major psychological impact of transforming oncology care to teleconferences and videoconferences and of the important strict recommendation of social distancing must not be overlooked in a patient population that is characterised by significant prevalence of cognitive decline and by the general perception that their life span may not exceed the life span of the COVID-19 pandemic.

BACKGROUND
The COVID-19 epidemic has changed the way medicine is practised almost throughout the world. Age has emerged as the most impressive risk factor of succumbing to COVID-19. Among the large population of elderly patients who are treated for COVID-19, there is a strong prevalence of cardiovascular and pulmonary comorbidity, which suggests that frailty rather than age confers susceptibility to COVID-19. Thus, the consideration that no resources should be invested into the elderly per se, for example, by withholding admission to intensive care units for patients with COVID-19 beyond a certain age, is therefore not only ethically questionable but also scientifically false. Further, in contrast to what might be expected, chronic immunosuppression and cancer do not seem to be major predictors of COVID-19 vulnerability, although few data are available on this topic so far. Limited reports on COVID-19 and cancer which stem from China indicate that the disease course of COVID-19 may be more severe in patients with cancer but do not allow to definitely conclude that cancer as such increases the risk of COVID-19, however likely this may seem. Among 1524 patients with cancer from a single institution in Wuhan, 12 patients (0.79%) had severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection, which was higher than the cumulative incidence of 0.37% of COVID-19 cases in the respective general population. However, it is inappropriate to conclude that patients seen at a cancer centre share the same risk factors of cardiopulmonary comorbidity and age as the general population. In a survey of 2007 COVID-19 cases from 575 hospitals in China, 18 patients had cancer, a figure that we do not interpret as evidence of strong associations between COVID-19 and cancer. The most common diagnosis was lung cancer (5 of 18 patients, 28%), and three-quarter of the patients (12 of 18) were not undergoing active anticaner therapy but were cancer survivors in routine follow-up. The authors stress that the rate of cancer among their patients with COVID-19 exceeds that of the general population, but without controlling for age and comorbidity; therefore, such figures need to be interpreted with caution.

Accordingly, we need to make sure that we as healthcare providers stay informed and that we provide sufficient information to patients and caregivers on the relative risks and benefits of all interventions, including antitumour treatments and supportive care. We need to outline that teleconferences and videoconsulting are valid alternatives,
although hopefully a transient measure only. There is a priori no evidence to suggest that coming to an outpatient visit to the hospital is more dangerous than going to visit relatives or for shopping. It is important to outline that it is not the hospital per se, but the number of other people encountered on the journey and the vigour with which social distancing is maintained that likely determines risk of infection. We must avoid inferior outcome of our patients simply because these are too afraid to come to the hospital when in fact they should. Finally, we also need to make sure that we maintain the specialised neuro-oncology workforce at our institutions, for example, by reorganising multidisciplinary tumour boards to remote conferences or conferences with one decision maker per discipline only.

CONSIDERATIONS THAT ARE NOT NEW BUT BECOME MORE PROMINENT DURING THE COVID-19 PANDEMIC

It is a common theme in neuro-oncology that therapeutic interventions for which there is no evidence should not routinely be offered to patients. It just seems to be so much easier for many healthcare providers and also caregivers to recommend specific medical interventions even in the absence of clear evidence, because it is perceived as easier and associated with less psychological burden than adequate advance care planning, including an honest weighing of the options. Typical interventions that are often questionable include serial operations for tumours that cannot be controlled surgically, repeat irradiation that is often combined with immunosuppressive steroids or ‘salvage’ chemotherapies beyond one or two alkylators for patients with gliomas, for example, platinum-based regimens or irinotecan. These are just a few important measures commonly encountered in clinical practice for which no supportive data from controlled trials exist. It is only now that many of us realise that we occasionally treat where we should not. Further, we should prudently weigh risk and benefit of systemic pharmacotherapy in all disease areas where there is little or no evidence for pharmacotherapy at all, not only in meningioma or ependymoma in adults but also in recurrent glioblastoma, where no intervention except nitrosoureas in patients with tumours with O6-methylguanine DNA methyltransferase (MGMT) promoter methylation is likely to confer meaningful disease control. The attitude towards too generous corticosteroid prescriptions has already changed in recent years, but the time has come now to verify the need for steroid medication in every patient, notably also during radiotherapy, where these agents are still occasionally given by default. On the other hand, treatments with clear benefits such as combined radiochemotherapy in MGMT promoter-methylated newly diagnosed glioblastoma should not be withheld from patients by default. This applies also to highly immunosuppressive treatments, such as high-dose chemotherapy in primary central nervous system lymphoma. Here, we have provided some key considerations for the management of brain tumor patients during the current COVID-19 pandemic (Box 1).

SPECIFIC COVID-19 PANDEMIC-RELATED RECOMMENDATIONS

There are also disease-specific considerations where the risk:benefit ratio has changed. It is common practice to scan patients with brain tumour in regular intervals even after years of stable disease without intervention. During the COVID-19 pandemic, we should explore whether we may delay repeat scanning and outpatient visits in patients in stable conditions who are asymptomatic. Radiotherapy schedules can probably be adapted to hypofractionation in defined patient populations, for example, patients with brain metastases or MGMT promoter-unmethylated glioblastoma, without compromising outcome, but with a major reduction in hospital visits. For systemic chemotherapy that is potentially immunosuppressive, including alkylating agent chemotherapy, dosing should be conservative and the thresholds for dose reductions may need to be lowered to improve safety, notably in diseases where prolonged exposure to treatment is probably needed, for example, lower WHO grade gliomas.

Nobody would dispute that temozolomide would not have been approved based on the data observed in the management of brain tumor patients during the current COVID-19 pandemic (Box 1).
patient population with glioblastoma lacking MGMT promoter methylation. Yet, given the doubts on the reliability of assessing the MGMT status and the lack of alternative drugs approved in the newly diagnosed setting, temozolomide has been maintained as standard of care for all patients matching the inclusion criteria of the registration trial. One might argue that the cons currently over-ruled the pros when evaluating temozolomide for patients with MGMT promoter-unmethylated glioblastoma, given the risk of lymphopaenia, repeated blood tests and overall more contact with the healthcare system. Scepticism regarding alkylating agent chemotherapy is even more appropriate in the recurrent setting, where neither temozolomide nor nitrosoureas offers major clinical benefit unless the MGMT promoter is methylated.

ACCESS TO INTERMEDIATE AND INTENSIVE CARE

The heated discussion on whether and which oncology patients suffering from COVID-19 or not should have access to intensive care medicine is an important one but, as yet in most countries, mainly a preparation for a feared scenario where capacities are truly limited and triage becomes important. This cannot be regulated by recommendations in *ESMO Open* or elsewhere, but strongly depends on local circumstances. What is important in the current situation is to indicate in any medical report somehow the overall prognosis of each patient to ascertain that those colleagues who have to make decisions under stress and time and resource limits are adequately informed. Patients with curatively operated tumours, for example, schwannomas or meningiomas, who have no evidence of recurrent disease must not be placed in the same category as patients with recurrent glioblastoma, but having a brain tumour is still often perceived as stigmatising.

CLINICAL TRIALS

Clinical trials deserve specific consideration in the situation of a pandemic as experienced now. Phase I trials seeking to establish maximum tolerated doses with uncertain individual patient benefit need to be viewed with caution unless the intervention is highly unlikely to compromise immune function or to cause pulmonary toxicity. For most phase II trials, patients already enrolled onto trials and being stable may be kept on trial with a careful risk:benefit ratio from the patient perspective, not from a trial perspective. Essentially, the same holds true for phase III trials; however, clinical trials evaluating novel treatments that are associated with immunosuppression raise ethical concerns: randomising in the current situation against a standard of care indicates that the benefit of the new intervention is uncertain, but the perceived risk of increased sensitivity to infection would seem to make it prohibitory to place patients on such trials. Particular concern applies to placebo-controlled trials in this situation. Resorting to teleconsultations and videoconsultations and allowing drug shipment to patients include a few measures that may maintain trial integrity without placing patients at undue risk. Importantly, several companies sponsoring clinical trials have put activities on hold already, and, again, many institutions have imposed their own rules on how clinical research is conducted, and these regulations obviously over-rule any outside recommendations.

PATIENTS WITH BRAIN TUMOUR WITH COVID-19 INFECTION

Finally, as time goes by, patients with brain tumour who have acquired COVID-19 infection will pose new challenges for neuro-oncologists. For patients symptomatic for COVID-19, it seems prudent to withhold any systemic chemotherapy, unless entirely non-immunosuppressive, and to challenge the need for steroids until patients have fully recovered from COVID-19. More complicated is the situation of patients with brain tumour tested for COVID-19 as part of a screen who come back positive but are asymptomatic for COVID-19. Here, a careful evaluation of risk and benefit is necessary, and moderate delays of systemic chemotherapy may be a preferred option.

Contributors MW and MP wrote the article. Both approved the final manuscript before submission.

Funding The authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors.

Competing interests MW has received research grants from Abbvie, Adacstra, Dracen, Merck, Sharp & Dohme ( MSD), Merck (EMD), Novocure, OGD2, Piqur and Roche, and honoraria for lectures or advisory board participation or consulting from Abbvie, Basiliea, Bristol Meyer Squibb, Celgene, MSD, Merck (EMD), Novocure, Orbis, Roche and Tocagen. MP has received honoraria for lectures, consultation or advisory board participation from the following for-profit companies: Bayer, Bristol-Myers Squibb, Novartis, Gerson Lehrman Group, CMS Contrast, GlaxoSmithKline, Mundipharma, Roche, Astra Zeneca, AbbWe, Lilly, Meda, Diehl, Daiichi Sankyo and MSD.

Patient consent for publication Not required.

Provenance and peer review Commissioned; externally peer reviewed.

Open access This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, any changes made are indicated, and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/.

ORCID iD Matthias Preussler http://orcid.org/0000-0003-3541-2315

REFERENCES

1. Zhang L, Zhu F, Xiao L, et al. Clinical characteristics of COVID-19-infected cancer patients: a retrospective case study in three hospitals within Wuhan, China. *Ann Oncol* 2020. doi:10.1016/j.annonc.2020.03.296.
2. Yu J, OuYang W, Chua MLK, et al. SARS-CoV-2 transmission in patients with cancer at a tertiary care hospital in Wuhan, China. *JAMA Oncol* 2020.
3. Liang W, Guan W, Chen R, et al. Cancer patients in SARS-CoV-2 infection: a nationwide analysis in China. *Lancet Oncol* 2020;21:335–7.
4. Hegi ME, Diserens A-C, Gorlia T, et al. MGMT gene silencing and benefit from temozolomide in glioblastoma. *N Engl J Med* 2005;352:997–1003.
5. Weller M, van den Bent M, Tonn JC, et al. European association for neuro-oncology (EANO) guideline on the diagnosis and treatment of adult astrocytic and oligodendroglioma gliomas. *Lancet Oncol* 2017;18:e315–29.
6. de Paula BHR, Araujo I, Bandeira L, et al. Recommendations from national regulatory agencies for ongoing cancer trials during the COVID-19 pandemic. *Lancet Oncol* 2020;21:624–7.